BioCentury | Sep 19, 2020
Politics, Policy & Law

What it will take to get to mass asymptomatic screening for COVID-19

Making widespread COVID-19 screening a priority for public health will require a broad and abundant basket of testing technologies, and a coordinated plan for how to use and pay for them. The first barrier...
BioCentury | Mar 20, 2020
Tools & Techniques

COVID-19 crisis brings CRISPR-Cas13 research into the spotlight

It makes sense that CRISPR-Cas13 would enter the limelight during the COVID-19 crisis, given that the SARS-CoV-2 is an RNA virus, and this Cas enzyme targets RNA. With diagnostics one of the most critical components...
BioCentury | Oct 30, 2019
Company News

Amgen narrows neuro focus to inflammation

...targets a distinct part of neural circuitry involved with migraine related to ADCYAP1R1. Targets: ADCYAP1R1 (PAC1...
BioCentury | Sep 16, 2019
Company News

Lundbeck enters migraine race with $2B takeout of Alder

Lundbeck will add a CGRP inhibitor to its neurology pipeline by buying Alder for just shy of $2 billion, but the Scandinavian pharma will be playing catch-up as eptinezumab will likely be fourth among drugs...
BioCentury | Sep 13, 2019
Company News

Vertex reaches CF deal in Scotland

After more than three years of negotiations, Vertex and Scotland have agreed to a five-year reimbursement agreement that gives cystic fibrosis patients access to two CF drugs, making Scotland the first in the U.K. to...
BioCentury | Aug 12, 2019
Company News

Vertex fails to reach CF deal in Scotland

Two of Vertex's cystic fibrosis drugs continue to remain unavailable in the U.K. after the Scottish Medicines Consortium rejected their coverage on NHS, citing a lack of long-term data to support the price. "As these...
BioCentury | May 20, 2019
Distillery Therapeutics

Analog of pleuromutilin identified for multiple cancers

DISEASE CATEGORY: Cancer INDICATION: Breast cancer; colorectal cancer; ovarian cancer; pancreatic cancer; solid tumors Cell culture and mouse studies identified a thioredoxin inhibitor that could help treat breast, ovarian, pancreatic and other cancers. Chemical synthesis...
BioCentury | Apr 1, 2019
Company News

Salix licenses new NASH target from UCLA

...ADCYAP1R1 (PAC1) - Adenylate cyclase activating polypeptide 1 pituitary receptor type I Sandi Wong, Staff Writer Bausch Health Companies Inc. Salix Pharmaceuticals Ltd. University of California Los Angeles Adenylate cyclase activating polypeptide 1 pituitary receptor type I...
...PAC1) - Adenylate cyclase activating polypeptide 1 pituitary receptor type I Sandi Wong, Staff Writer Bausch Health Companies Inc. Salix Pharmaceuticals Ltd. University of California Los Angeles Adenylate cyclase activating polypeptide 1 pituitary receptor type I (ADCYAP1R1...
...Adenylate cyclase activating polypeptide 1 pituitary receptor type I Sandi Wong, Staff Writer Bausch Health Companies Inc. Salix Pharmaceuticals Ltd. University of California Los Angeles Adenylate cyclase activating polypeptide 1 pituitary receptor type I (ADCYAP1R1) (PAC1) Adenylate...
BioCentury | Jan 23, 2019
Distillery Therapeutics

Neurology

INDICATION: Migraine In vitro and rat studies identified a mAb against the ADCYAP1-derived peptides PACAP-38 and PACAP-27 that could help treat migraine. In vitro screening of B cell cultures of PACAP-38-immunized rabbits for mAbs that...
BioCentury | Dec 21, 2018
Company News

U.K. committee releases Orkambi documents; pricing details lacking

As NICE, NHS England and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) remain at an impasse over the pricing of cystic fibrosis drug Orkambi ivacaftor/lumacaftor, a U.K. parliamentary committee made good on its promise on Dec. 20, releasing...
Items per page:
1 - 10 of 89